Skip to main content

Human Papillomavirus Associated Intraepithelial Neoplasia

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

RinuaGene Biotechnology
1 program
1
RG002 injectionPhase 1/21 trial
Active Trials
NCT06273553Not Yet Recruiting39Est. Dec 2027

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
RinuaGene BiotechnologyRG002 injection

Clinical Trials (1)

Total enrollment: 39 patients across 1 trials

A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3

Start: Mar 2024Est. completion: Dec 202739 patients
Phase 1/2Not Yet Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.